regeneus
living regenerative medicine



# John Martin
# CEO

## Regeneus Ltd (ASX:RGS)

**Hong Kong 13 March 2018**
**Shanghai 15 March 2018**

ASIAN INVESTMENT SERIES 2018
13 March 2018 KPMG Hong Kong | 15-16 March 2018 KPMG Shanghai
HONG KONG BIOTECH INVEST & PARTNERING | AUSTRALIA-CHINA BIOTECH INVEST & PARTNERING

AusBiotech Investment
AUSTRALIA'S BIOTECHNOLOGY ORGANISATION

# Disclaimer

**Forward-Looking Statements**

This Presentation contains certain statements which constitute forward-looking statements or information ("forward-looking statements"). These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding the general economic and industry conditions in Australia and globally and the operations of the Company. These factors and assumptions are based upon currently available information and the forward-looking statements contained herein speak only as of the date hereof. Although the Company believes the expectations and assumptions reflected in the forward-looking statements are reasonable, as of the date hereof, undue reliance should not be placed on the forward-looking statements as the Company can give no assurances that they will prove correct and because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include, but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; risks associated with biotechnology companies, regenerative medicine and associated life science companies; delays or changes in plans; specific risks associated with the regulatory approvals for or applying to the Company's products; commercialisation of the Company's products and research and development of the Company's products; ability to execute production sharing contracts, ability to meet work commitments, ability to meet the capital expenditures; risks associated with stock market volatility and the ability of the Company to continue as a going concern. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by securities laws.

**No offer to sell, issue or recommend securities**

This document does not constitute an offer, solicitation or recommendation in relation to the subscription, purchase or sale of securities in any jurisdiction. Neither this presentation nor anything in it will form any part of any contract for the acquisition of securities.

# Corporate Overview

**Regeneus Ltd (ASX: RGS) -** Australian-based clinical-stage **regenerative medicine** company

- Regeneus is developing a **portfolio of novel cell-based therapies**, using stem cell and immuno-oncology technologies
- These therapies will **address unmet medical needs in the human and animal health markets** and focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology
- **Technology is validated** by positive preclinical and clinical data; collaboration with AGC, leading biopharma manufacturer in Japan; and substantial IP portfolio >70 patents and patent applications
- Regeneus is only the 17th Australian company to have secured a significant technology licensing agreement in Japan over the past 20 years

| ASX code | RGS |
|---|---|
| Share price (8 Mar 18) | $0.11 |
| 52 week | $0.10 - $0.16 |
| Market Capitalisation | 23 million |
| Shares on issue | 209 million |
| Options[1] | 10 million |
| Board & Executives shares/options | 20% |
| Cash (31 Dec 17) | $3.4 million |
| Undrawn loan facility | $2.0 million |
| Investment since commencement 2009 | |
| Capital raised | $31 million |
| R&D expenditure | $40 million |
| R&D tax incentive received | $18 million |
| Total cash invested | $61 million |

**Share price Chart**




Regeneus ASX Health Care Index including RGS

1. Average Exercise Price $0.22

# Global Regenerative Medicine Market

regeneus
living regenerative medicine

- The global regenerative medicine market is extremely large, high-growth market expected to reach **US$380 billion by 2050**
- 4th therapeutic pillar of global healthcare (alongside pharmaceuticals, biologics and devices)
- Regulatory changes enhancing opportunity
  - US FDA 21st Century Cures Act
  - Japan PMD Act
  - Europe ATMP designation




*Japan's Ministry of Education Trade & Industry

# Development Pipeline

regeneus
living regenerative medicine

## *Human Health Development Pipeline*

| Program | Technology Platform | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Approval |
|---|---|---|---|---|---|---|
| Progenza | Allogeneic Adipose MSCs & Secretions | Osteoarthritis | | | | |
| | | Pain | | | | |
| RGSH4K | Immunotherapy for oncology | Solid Tumours | | | | |
| Sygenus | Allogeneic Adipose MSC Secretions | Dermatology | | | | |
| | | Pain | | | | |

## *Animal Health Development Pipeline*

| Program | Technology Platform | Manufacturing & Process Development | Safety & Efficacy Studies | Pivotal Trial | Market Approval |
|---|---|---|---|---|---|
| CryoShot Canine | Allogeneic Adipose MSCs | Osteoarthritis | | | |
| CryoShot Equine | Allogeneic Adipose MSCs | Osteoarthritis | | | |
| Kvax | Immunotherapy for oncology | Naturally Occurring Advanced Cancers (Conditional Approval)) | | | |

# Osteoarthritis: Significant Unmet Need

regeneus
living regenerative medicine

- Single **most common cause of disability** in adults with no cure
  - Prevalence of >33% in adults aged >65 years

- Major risk factors:
  - Advancing age

    *" By 2020, for the first time in history, the number of people aged 60 years and older will outnumber children younger than 5 years"*

    World Health Organization
  - Gender (female)
  - Increasing BMI

    *"Globally 39% of adults are overweight and 13% obese (obesity has tripled since 1975)"*

- With no cure, and **only symptomatic relief**, current market is dominated by pain relief or joint replacement



# Progenza: Proprietary and Scalable Stem Cell Platform

regeneus
living regenerative medicine

Progenza is a patented, scalable, off-the-shelf stem cell technology platform **to treat a range of inflammatory conditions**


- Progenza mesenchymal stem cells (MSCs) are sourced from a healthy adult donor
  - high safety and tolerability profile - no reprogramming or genetic modification of cells with lower clinical and regulatory risk
  - no requirement for expensive recombinant growth factors in production process
- Adipose (fat) tissue has competitive advantages as the source for MSCs
  - large starting volume and large number of MSCs in adipose vs. other sources
  - scalable technology – capacity to produce millions of Progenza doses from one donor
  - Better modification of immune response

# Progenza: Secretions Create Competitive Advantage

*MSCs secrete a diverse variety of bioactive factors including cytokines, growth factors, extracellular vesicles and exosomes*

*Secretions respond to the local environment and are the driving force for reducing inflammation, promoting tissue repair and reducing scarring*

Progenza has a competitive advantage over other MSC products as it includes secretions with cells which:

- improves viability, stress resistance and functionality of cells
- provide protection for cells to improve proliferation post thawing compared to cryoprotective solutions
- minimises cell loss post thawing and improves cell viability and functionality







**Cryopreserved cells vs Progenza: pre- and post- stress**

# Progenza: Third-Party Validation

regeneus
living regenerative medicine

## Positive Phase 1 Trial Results

**Positive results from STEP Phase 1 safety trial** in patients with knee osteoarthritis published in the **Journal of Translational Medicine**

## World-leading Manufacturer

**AGC Asahi Glass** a world-leading leading biopharma manufacturer in Japan **will manufacture Progenza**

Upfront fee received in FY17

## Strong IP

**>70 patents** or patent applications across **14 patent families**

**STEP Phase 1 Safety Trial of Progenza** in patients with knee osteoarthritis:

- Primary endpoints met - safe and well tolerated
- Secondary endpoints:
  - clinically meaningful and durable pain relief
  - statistically significant improvement in lateral tibial cartilage volume versus placebo

# Value Creation Catalysts

regeneus
living regenerative medicine

**Targeting second Progenza licence, following successful monetisation of initial Progenza licence in Japan**

| | |
|---|---|
| **Progenza** | |
| • STEP trial manuscript published | Q3 FY18 |
| • Secure initial commercialisation/clinical partner for Progenza in Japan | H2 FY18 |
| • Identify partners for further indications and territories for Progenza | ongoing |
| **Sygenus** | |
| • Further product development to target specific pain and dermatological indications | H2 FY18 |
| • Explore licencing opportunities for pain & dermatology | FY19 |
| **RGSH4K** | |
| • Recruitment for ACTIVATE trial closed and report trial results | H2 FY18 |
| • Advance clinical partnering discussions with further trial data | ongoing |
| **CryoShot** | |
| • Finalise recruitment and report results | FY19/20 |
| **Kvax** | |
| • Finalise recruitment for B cell lymphoma trial and report results | FY19/20 |

# Investment Summary

- ✓ Global regenerative medicine market presents a strong and growing market opportunity, estimated to be worth US$380 billion by 2050
- ✓ Regeneus well positioned with validated, scalable and commercially viable technology combine with a successful licence driven business model
- ✓ Multiple licence opportunities for Regeneus' portfolio of assets across each platform, jurisdiction and clinical application
- ✓ Validated technology through commercial partnership, published results and regulatory approvals
- ✓ Japan presents a growing opportunity with more commercial deals in the pipeline
- ✓ Strong management team with expertise in developing and commercialising regenerative medical technology
- ✓ Significant value creation milestones over the next 6-12 months

# Contact

Sandra McIntosh

Company Secretary
& Investor Relations
M: +61 450 253 059
P: +61 2 9499 8010
E: investors@Regeneus.com.au